PMID- 18394821
OWN - NLM
STAT- MEDLINE
DCOM- 20080826
LR  - 20181201
IS  - 0369-8114 (Print)
IS  - 0369-8114 (Linking)
VI  - 56
IP  - 4
DP  - 2008 Jun
TI  - [Treatment of venous thromboembolic disease in cancer patients].
PG  - 220-8
LID - 10.1016/j.patbio.2008.02.007 [doi]
AB  - Venous thromboembolism (VTE) disease, as defined by the occurrence of deep venous 
      thrombosis or pulmonary embolism, occurs among 4 to 20% of patients with cancer 
      and is a leading cause of death among these patients. Use of classical 
      anticoagulation to treat VTE in a cancer patient is associated with a higher risk 
      of major bleeding and of VTE recurrence as compared to noncancer patients. 
      Updated comprehensive and systematic review of current data from the medical 
      literature allows to reconsider the classical approach used for anticoagulant 
      treatment in cancer patients and to implement adapted recommendations. In 2008, 
      the use of daily subcutaneous low-molecular-weight heparin (LMWH) for at least 
      three to six months is recommended as first line therapy to treat VTE disease in 
      cancer patients. If LMWH are contra-indicated (renal insufficiency), other 
      therapeutic approaches are warranted, such as use of unfractionated heparin (UFH) 
      with early introduction of anti-vitamin K for at least three months or venous 
      cava filter in case of absolute contra-indications to anticoagulation. VTE 
      prophylaxis in cancer patients relies on the same therapeutic approaches as 
      currently used for noncancer patients at high risk of VTE. The definition of more 
      specific prophylactic approaches for patients with cancer considered at higher 
      risks of VTE, will be the subject of many clinical trials in the forthcoming 
      years.
FAU - Farge-Bancel, D
AU  - Farge-Bancel D
AD  - Service de medecine interne et pathologie vasculaire, base moleculaires de 
      l'homeostasie cutanee, Inserm U67, hopital Saint-Louis, 10, avenue 
      Claude-Vellefaux, 75010 Paris, France. dominique.farge-bancel@sls.aphp.fr 
      <dominique.farge-bancel@sls.aphp.fr>
FAU - Florea, L
AU  - Florea L
FAU - Bosquet, L
AU  - Bosquet L
FAU - Debourdeau, P
AU  - Debourdeau P
LA  - fre
PT  - Journal Article
PT  - Review
PT  - Systematic Review
TT  - Traitement de la maladie thromboembolique veineuse chez le cancereux.
DEP - 20080403
PL  - France
TA  - Pathol Biol (Paris)
JT  - Pathologie-biologie
JID - 0265365
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants/adverse effects/therapeutic use
MH  - Brain Neoplasms/complications
MH  - Heparin/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Neoplasms/*complications
MH  - Pulmonary Embolism/drug therapy
MH  - Risk Factors
MH  - Venous Thromboembolism/complications/*drug therapy/prevention & control
MH  - Venous Thrombosis/drug therapy/prevention & control
MH  - Warfarin/therapeutic use
RF  - 60
EDAT- 2008/04/09 09:00
MHDA- 2008/08/30 09:00
CRDT- 2008/04/09 09:00
PHST- 2007/12/10 00:00 [received]
PHST- 2008/02/11 00:00 [accepted]
PHST- 2008/04/09 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/04/09 09:00 [entrez]
AID - S0369-8114(08)00032-1 [pii]
AID - 10.1016/j.patbio.2008.02.007 [doi]
PST - ppublish
SO  - Pathol Biol (Paris). 2008 Jun;56(4):220-8. doi: 10.1016/j.patbio.2008.02.007. 
      Epub 2008 Apr 3.